Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab209920-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$109.90
|
|
|
Ab209920-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$509.90
|
|
|
Ab209920-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,399.90
|
|
|
Ab209920-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,299.90
|
|
Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) - Primary antibody, specific to MAGEA3, Human IgG1 |
|---|---|
| Synonyms | Antigen MZ2 D antibody | Antigen MZ2-D antibody | Cancer/testis antigen 1.3 antibody | Cancer/testis antigen family 1 member 3 antibody | CT1.3 antibody | HIP8 antibody | HYPD antibody | MAGA3_HUMAN antibody | MAGE 3 antigen antibody | MAGE family member |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or sta |
| Host species | Human |
| Specificity | MAGEA3 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) is an antibody that targets MAGE-A. It can be used in the treatment of metastatic cancer treatment. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 150 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) (Ab209920) - Flow Cytometry
Flow Cytometry analysis of HCC1428 cells labelling MAGEA3 at 1×105 cell/well can bind CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) (Ab209920).
CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) (Ab209920) - SEC
The purity of CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) (Ab209920) is more than 95% verified by HPLC.